MDL 74722

Drug Profile

MDL 74722

Latest Information Update: 04 Jul 2002

Price : $50

At a glance

  • Originator Nordic
  • Class Anti-ischaemics; Benzofurans; Neuroprotectants
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral infarction; Cerebral ischaemia; Cerebrovascular disorders

Most Recent Events

  • 17 Mar 1998 A preclinical study has been added to the pharmacodynamics section
  • 17 Mar 1998 Preclinical development for Cerebrovascular disorders in France (Unknown route)
  • 17 Mar 1998 Preclinical development for Cerebral ischaemia in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top